A5001167896- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Meningioma and schwannoma management
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Medical Imaging Techniques and Applications
- Cell Image Analysis Techniques
- Computational Drug Discovery Methods
- Neuroblastoma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Metabolomics and Mass Spectrometry Studies
- Angiogenesis and VEGF in Cancer
- Ferroptosis and cancer prognosis
- Cancer, Lipids, and Metabolism
- Histone Deacetylase Inhibitors Research
- Head and Neck Surgical Oncology
- Lymphoma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Migraine and Headache Studies
Essen University Hospital
2017-2025
University of Duisburg-Essen
2018-2025
Deutschen Konsortium für Translationale Krebsforschung
2018-2025
Heinrich Heine University Düsseldorf
2023-2025
Düsseldorf University Hospital
2023-2025
University Hospital Bonn
2012-2025
Katholisches Klinikum Lünen/Werne , St.-Marien-Hospital Lünen
2025
Klinik und Poliklinik für Neurologie
2017-2024
West German Heart and Vascular Center Essen
2018-2024
German Cancer Research Center
2019-2024
The tyrosine kinase c-Met promotes the formation and malignant progression of multiple cancers. It is well known that hyperactivation increases tumorigenicity tumor cell resistance to DNA damaging agents, properties associated with tumor-initiating stem cells. However, a link between signaling and/or maintenance neoplastic cells has not been previously identified. Here, we show activated functional in glioblastoma (GBM) neurospheres enriched for expression/function correlates marker...
In patients with newly diagnosed glioblastoma that harbors a nonmethylated O(6)-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ.In this phase II, unblinded 182 in 22 centers were randomly assigned 2:1 BEV (10 mg/kg every 2 weeks) during radiotherapy (RT) followed by maintenance IRI(125 mg/m(2) or daily TMZ (75 mg/m(2)) RT six courses of...
Research Article14 December 2015Open Access Source Data Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma Alexander Scholz Institute of Neurology (Edinger Institute), Goethe University Medical School, Frankfurt, Germany Search for more papers by this author Patrick N Harter German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Sebastian Cremer Burak H Yalcin Stefanie Gurnik Maiko Yamaji Mariangela Di Tacchio...
Abstract Purpose: Glioblastoma is a highly malignant, invariably fatal brain tumor for which effective pharmacotherapy remains an unmet medical need. Experimental Design: Screening of compound library 160 synthetic and natural toxic substances identified the antihelmintic niclosamide as previously unrecognized candidate clinical development. Considering cellular interindividual heterogeneity glioblastoma, portfolio short-term expanded primary human glioblastoma cells (pGBM; n = 21), common...
To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblastoma and treated combination lomustine (CCNU), temozolomide (TMZ), radiotherapy.Thirty-nine received radiotherapy the tumor site only (60 Gy) CCNU/TMZ chemotherapy (n = 31 standard-dose CCNU, 100 mg/m2 on day 1 TMZ mg/m(2)/d days 2 to 6; n 8 intensified-dose CCNU 110 mg/m(2) 150 6) for up six courses.In whole cohort, median overall (mOS) was 23.1 months; 47.4% survived years, 18.5% 4 years. After...
Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection. Their resistance to postsurgical therapy is considered a major driving force mortality, but their biology remains largely uncharacterized. In this study, residual were derived via experimental biopsy resection margin after standard neurosurgery for direct comparison with samples from routinely resected tissue. vitro analysis proliferation, invasion, stem cell qualities, GBM-typical antigens, genotypes, and...
Pseudoprogression (PsP) is characterized by therapy-associated but not tumor growth-associated increases of contrast-enhancing glioblastoma lesions on MRI. Although typically occurring during the first 3 months after radiochemotherapy, PsP may occur later in course disease and then be particularly difficult to distinguish from true progression. We explored PET using O-(2-[(18)F]fluoroethyl)-L-tyrosine ((18)F-FET-PET) approach diagnostic dilemma.Twenty-six patients with that presented...
Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is only CGRP mAB targeting receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients not available, yet, although many treated with under real world conditions can be considered as therapy-refractory.Clinical routine 70 mg for 3 months between November 2018 December 2019 West German Headache Center, University...
Abstract Glioblastoma (GBM) is a non-T-cell–inflamed cancer characterized by an immunosuppressive microenvironment that impedes dendritic cell maturation and T-cell cytotoxicity. Proangiogenic cytokines such as VEGF angiopoietin-2 (Ang-2) have high expression in glioblastoma cell-specific manner not only drive tumor angiogenesis vascular permeability but also negatively regulate T-lymphocyte innate immune responses. Consequently, the alleviation of immunosuppression might be prerequisite for...
BackgroundMedian survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated long-term remain poorly defined.MethodsEuropean Organization Research Treatment Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by Brain Tumor Funders Collaborative US EORTC Group. Patients surviving at least years from diagnosis were identified 24 sites Europe, US, Australia. In isocitrate...
Abstract Background Glioblastomas are characterized by aggressive and infiltrative growth, striking heterogeneity. The aim of this study was to investigate whether tumor cell proliferation invasion interrelated, or rather distinct features different populations. Methods Tumor were longitudinally determined in real-time using 3D vivo 2-photon laser scanning microscopy over weeks. Glioblastoma cells expressed fluorescent markers that permitted the identification their mitotic history cycling...
To assess the diagnostic accuracy of <sup>68</sup>Ga-labeled fibroblast activation protein inhibitor (FAPI) and <sup>18</sup>F-labeled FDG PET for detection various tumors, we performed a head-to-head comparison both imaging modalities across range tumor entities as part our ongoing <sup>68</sup>Ga-FAPI observational trial. <b>Methods:</b> The study included 115 patients with 8 who received staging or restaging between October 2018 March 2022. Of those, 103 concomitant <sup>18</sup>F-FDG had...
Abstract The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part GLORIA (NCT04121455), a phase I/II trial combining RT and CXCL12-neutralizing aptamer olaptesed pegol (NOX-A12; 200/400/600 mg per week) in patients with incompletely resected, newly-diagnosed GBM lacking MGMT methylation. primary endpoint was safety, secondary endpoints included maximum tolerable dose (MTD),...
The ecosystem of brain tumors is considered immunosuppressed, but our current knowledge may be incomplete. Here we analyzed clinical cell and tissue specimens derived from patients presenting with glioblastoma or nonmalignant intracranial disease to report that the cranial bone (CB) marrow, in juxtaposition treatment-naive tumors, harbors active lymphoid populations at time initial diagnosis. Clinical anatomical imaging, single-cell molecular immune profiling quantification tumor reactivity...
Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation therapy, yet, determining the status is most challenging recurrent glioblastoma (GBM) where patients not eligible for second-line surgery. Because very little known on consistency along clinical course we here explored common drug targets paired primary vs. GBM tissue samples. Paired...
Investigation of clonal heterogeneity may be key to understanding mechanisms therapeutic failure in human cancer. However, little is known on the consequences intervention composition solid tumors.Here, we used 33 single cell-derived subclones generated from five clinical glioblastoma specimens for exploring intra- and interindividual spectra drug resistance profiles vitro In a personalized setting, explored whether differences pharmacologic sensitivity among could employed predict...
Abstract STUDY QUESTION Does endometrial scratching in women with one failed IVF/ICSI treatment affect the chance of a live birth subsequent fresh cycle? SUMMARY ANSWER In this study, 4.6% more births were observed scratch group, likely certainty range between −0.7% and +9.9%. WHAT IS KNOWN ALREADY Since first suggestion that might improve embryo implantation during IVF/ICSI, many clinical trials have been conducted. However, due to limitations sample size study quality, it remains unclear...